Amgen (NASDAQ: AMGN) today announced that it will present data from multiple Kyprolis® (carfilzomib) for Injection, BLINCYTO® (blinatumomab), oprozomib and ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE